July 10, 2020

The Niche

Knoepfler lab stem cell blog

Month: January 2018

2 min read

Florida is a hot mess on the for-profit stem cell clinic front. My own state of California isn’t much better and actually has a great number of clinics, but more problems are coming to light in Florida, at least at this point. Now WLRN reports that a legislator in Florida has proposed a new bill to try to address some of the issues with the clinics. Many clinics in Florida are making money from vulnerable patients and in some cases have apparently caused them harm, including claimed …Read More

4 min read

Are you a risk-taker or do you do everything possible to avoid risks? Taking risks in science is necessary, but is there a wise way to take the risks you do? Science and medicine need a certain amount of risk and risk-takers to make transformative leaps forward. The risks in biomedical science can be conceptual (a eureka! moment of a new hypothesis you are going to put out there) or more practical such as inventing a new device or method. As to the former, …Read More

5 min read

The news that CRISPR-Cas9 gene editing in its current form may not work in a substantial fraction of people due to many of us having immunity to Cas9 came as a shock to many, but if you think about it, maybe it’s not so surprising. I don’t see it as the end of the world. A (preprint) from a group led by Matthew Porteus started this lively discussion a few days ago. The preprint is entitled, “Identification of Pre-Existing Adaptive Immunity to Cas9 Proteins in Humans.” Some people are freaking …Read More

4 min read

The FDA started off 2018 with a bang on the direct-to-consumer stem cell clinic front with a warning letter on January 3rd to American CryoStem, a firm involved in processing and distributing adipose stem cells. The company’s ATCELL™ adipose stem cell product was the focus of much of letter. The FDA indicated in the warning letter and in an accompanying press release (PR) that ATCELL™ is not minimally manipulated and that its administration did not qualify as homologous use. For these reasons, the letter …Read More